Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project

Background: Around 40% of ER+/HER2-breast carcinomas (BC) present mutations in the PIK3CA gene. Assessment of PIK3CA mutational status is required to identify patients eligible for treatment with PI3Kα inhibitors, with alpelisib currently the only approved tyrosine kinase inhibitor in this setting....

Descripción completa

Detalles Bibliográficos
Autores principales: Peixoto, Ana, Cirnes, Luís, Carvalho, Ana Luísa, Andrade, Maria João, Brito, Maria José, Borralho, Paula, Borralho, Pedro M., Carneiro, Ana Sofia, Castro, Lisandra, Correia, Lurdes, Dionísio, Maria Rita, Faria, Carlos, Figueiredo, Paulo, Gomes, Ana, Paixão, Joana, Pinheiro, Manuela, Prazeres, Hugo, Ribeiro, Joana, Salgueiro, Natália, Schmitt, Fernando C., Silva, Fátima, Silvestre, Ana Rita, Sousa, Ana Carla, Almeida-Tavares, Joana, Teixeira, Manuel R., André, Saudade, Machado, José Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941536/
https://www.ncbi.nlm.nih.gov/pubmed/36825198
http://dx.doi.org/10.3389/fmolb.2023.1082915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941536/
https://www.ncbi.nlm.nih.gov/pubmed/36825198
http://dx.doi.org/10.3389/fmolb.2023.1082915

Ejemplares similares